https://www.selleckchem.com/products/nlg919.html
3% vs. 61.9%; P= .02). Subgroup analyses indicated that patients in the PTR group seemed to get little survival benefit from the reuse of trastuzumab compared with those without trastuzumab (26 months vs. 28 months; P= .8. However, in the non-PTR group, re-treatment with trastuzumab in the metastatic setting prolonged the survival of patients compared to those without trastuzumab (not reached vs. 34 months; P=.04). This study verified the rationality of present definition of PTR after (neo)adjuvant trastuzumab. Patients with PTR did ha
Like
Comment
Share
